NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Get Started

$68.97 -0.23 (-0.33 %)

(As of 11/19/2018 11:17 AM ET)

Previous Close$69.20

Today's Range$68.59 - $69.24

52-Week Range$64.27 - $89.54

Volume2.02 million shs

Average Volume7.46 million shs

Market Capitalization$89.52 billion

P/E Ratio8.06

Dividend Yield3.29%

Beta1.01

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; and AELIX Therapeutics S.L. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:GILD

Previous Symbol

CUSIP37555810

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.09

Current Ratio3.45

Quick Ratio3.37

Price-To-Earnings

Trailing P/E Ratio8.06

Forward P/E Ratio10.71

P/E Growth-2.68

Sales & Book Value

Annual Sales$26.11 billion

Price / Sales3.42

Cash Flow$9.5925 per share

Price / Cash7.19

Book Value$15.69 per share

Price / Book4.40

Profitability

EPS (Most Recent Fiscal Year)$8.56

Net Income$4.63 billion

Net Margins7.12%

Return on Equity39.32%

Return on Assets12.73%

Miscellaneous

Employees10,000

Outstanding Shares1,293,620,000

Market Cap$89.52 billion

OptionableOptionable

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, October 25th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.57 per share on Friday, December 28th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend is Thursday, December 13th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Thursday, October, 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.63 by $0.21. The biopharmaceutical company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period last year, the business earned $2.27 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

19 Wall Street analysts have issued 12 month target prices for Gilead Sciences' stock. Their forecasts range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.6250 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)
2. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The launch of Yescarta is progressing well in the United States and the approval in Europe will further boost sales. Meanwhile, Gilead is intending to foray into the nonalcoholic steatohepatitis (NASH) and inflammation market with late-stage candidates, selonsertib and filgotinib, respectively. A tentative approval will diversify Gilead’s portfolio. Shares have outperformed the industry in the year so far. However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure. The departure of the CEO at this crucial time further clouds the growth prospects of the company." (9/25/2018)
3. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
4. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
5. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)

Has Gilead Sciences been receiving favorable news coverage?

News coverage about GILD stock has trended very positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a daily sentiment score of 3.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 15,046,053 shares, an increase of 13.8% from the September 28th total of 13,219,532 shares. Based on an average trading volume of 6,495,748 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.2% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN) and Halozyme Therapeutics (HALO).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

Dr. John F. Milligan, CEO, Pres & Director (Age 57)
Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
Mr. Kevin B. Young, Advisory (Age 60)
Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
Sung Lee, VP of Investor Relations

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.87%), Capital Research Global Investors (5.40%), Bank of New York Mellon Corp (2.42%), FMR LLC (1.40%), Dodge & Cox (1.27%) and Capital International Investors (1.06%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., State Treasurer State of Michigan, Mitsubishi UFJ Trust & Banking Corp, FMR LLC, Capital International Investors, Platinum Investment Management Ltd. and Franklin Resources Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which major investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capital Research Global Investors, Skandinaviska Enskilda Banken AB publ, Swedbank, TIAA CREF Investment Management LLC, Renaissance Technologies LLC, Prudential Financial Inc. and Capital World Investors. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $68.97.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $89.52 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		1,947 (Vote Outperform)
Underperform Votes:		833 (Vote Underperform)
Total Votes:		2,780

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 11/19/2018 by MarketBeat.com Staff

Featured Article: How is a Moving Average Calculated?